Randox Laboratories Completed Feasibility

January 6, 2011

For Immediate Release


Randox Laboratories Completed Feasibility

Clinical Laboratory Fee Schedule boosts reimbursement for AspirinWorks,
the only FDA-cleared test that measures urinary 11dhTxB2 to assess aspirin effect

DENVER — January 6, 2011 — The AspirinWorks® Test from Corgenix Medical Corporation (OTC BB: CONX), reimbursed under CPT code 84431, has received a 28 percent increase in reimbursement according to the 2011 Clinical Laboratory Fee Schedule. The fee schedule is published annually by the Centers for Medicare and Medicaid Services (CMS).

“This is encouraging news for the AspirinWorks Test, and it accurately reflects a more reasonable reimbursement rate for clinical laboratories,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “The increased reimbursement rate should enable more medium-sized clinical laboratories to enter the market, increasing the number of labs that run the AspirinWorks Test.”

The AspirinWorks Test is the only FDA-cleared test to measure thromboxane metabolites. It is reimbursed for clinical laboratories under two Current Procedural Terminology (CPT) codes. CPT codes are the most widely accepted form of medical nomenclature used to report medical procedures and services.

Clinical laboratories that run the AspirinWorks Test use a combination of two codes: 84431 for thromboxane metabolites (also known as AspirinWorks/11dhTxB2) and 82570 for the urinary creatinine measurement. The CMS National Limit for CPT code 84431 was increased 30 percent over the 2010 rate; however, a two percent across-the-board reduction for CMS tests in the CPT system resulted in an overall 19 percent increase in total clinical laboratory reimbursement for the AspirinWorks Test from $25.95 in 2010 to $30.92 in 2011.

The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to determine aspirin effect in apparently healthy individuals post ingestion. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy. Numerous peer-reviewed studies have shown that not everyone benefits from the same dose of aspirin.

Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe,” “estimate,” “project,” “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
E-mail : wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
E-mail: dan@armadamedical.com